Article
Multidisciplinary Sciences
Daniele Simoneschi, Gergely Rona, Nan Zhou, Yeon-Tae Jeong, Shaowen Jiang, Giacomo Milletti, Arnaldo A. Arbini, Alfie O'Sullivan, Andrew A. Wang, Sorasicha Nithikasem, Sarah Keegan, Yik Siu, Valentina Cianfanelli, Emiliano Maiani, Francesca Nazio, Francesco Cecconi, Francesco Boccalatte, David Fenyo, Drew R. Jones, Luca Busino, Michele Pagano
Summary: The research identifies AMBRA1 as a ubiquitin ligase that degrades D-type cyclins, whose loss leads to accumulation of D-type cyclins and tumorigenesis. Furthermore, AMBRA1 also affects the sensitivity to CDK4/6 inhibitors.
Article
Oncology
Eva Quandt, Nuria Masip, Sara Hernandez-Ortega, Abril Sanchez-Botet, Laura Gasa, Ainhoa Fernandez-Elorduy, Sara Plutta, Joan Marc Martinez-Lainez, Samuel Bru, Pau M. Munoz-Torres, Martin Floor, Jordi Villa-Freixa, May C. Morris, August Vidal, Alberto Villanueva, Josep Clotet, Mariana P. C. Ribeiro
Summary: Through yeast two-hybrid screening, we identified 10 new atypical cyclin-CDK complexes, including an active complex between CDK6 and cyclin I (CCNI) against retinoblastoma protein. Upregulation of CCNI increased breast cancer cell proliferation in vitro and in vivo, similar to the effect of cyclin D upregulation, but this effect was abolished by CDK6 silencing or palbociclib treatment. CCNI downregulation led to a decrease in cell number and a reduction in the percentage of cells reaching S phase. CCNI upregulation was also associated with high expression of E2F target genes in cancer cell lines and breast cancer tissue samples.
MOLECULAR ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Anne Yagolovich, Alina A. Isakova, Artem A. Artykov, Yekaterina V. Vorontsova, Diana Mazur, Nadezhda Antipova, Marat S. Pavlyukov, Mikhail Shakhparonov, Anastasia M. Gileva, Elena A. Markvicheva, Ekaterina A. Plotnikova, Andrey A. Pankratov, Mikhail P. Kirpichnikov, Marine E. Gasparian, Dmitry A. Dolgikh
Summary: In this study, the antitumor activity of DR5-B was improved by fusion with a tumor-homing iRGD peptide, resulting in a promising candidate for targeted therapy for glioblastoma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Barbara Toffoli, Federica Tonon, Veronica Tisato, Giorgio Zauli, Paola Secchiero, Bruno Fabris, Stella Bernardi
Summary: TRAIL induces apoptosis in cancer cells, while its effects in normal cells remain unclear. Studies have shown that TRAIL treatment reduces weight gain, insulin resistance, and inflammation in high-fat diet mice, and promotes skeletal muscle free fatty acid oxidation. Both in vitro and in vivo data demonstrate that TRAIL enhances AKT phosphorylation, skeletal muscle differentiation, and glucose uptake, suggesting therapeutic potential for metabolic disturbances and muscle mass loss associated with diabetes.
CELL DEATH & DISEASE
(2021)
Article
Biology
Dongjin Jeong, Hye Sung Kim, Hye Young Kim, Min Jueng Kang, Hyeryeon Jung, Yumi Oh, Donghyun Kim, Jaemoon Koh, Sung-Yup Cho, Yoon Kyung Jeon, Eun Bong Lee, Seung Hyo Lee, Eui-Cheol Shin, Ho Min Kim, Eugene C. Yi, Doo Hyun Chung
Summary: This study shows that sFasL interacts with DR5 to promote inflammation, potentially enhancing it through the CX3CL1-CX3CR1 axis. The interaction plays a role in autoantibody-induced arthritis, possibly mediated through the NF-kappa B pathway.
Review
Dermatology
Pengfei Sun, Zhensheng Hu, Bo Pan, Xiaosheng Lu
Summary: Keloid is a common disease in plastic surgery, with poor treatment effects using methods such as drug injection, surgical resection, cryotherapy, and laser treatment. The discovery of TRAIL in 1995 has led to its potential use in targeting tumors, and recent research has shown its potential in treating keloids by inducing fibroblast apoptosis through TRAI binding to its receptor.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2021)
Article
Medicine, Research & Experimental
Federica Laudisi, Teresa Pacifico, Claudia Maresca, Anderson Luiz-Ferreira, Sara Antonelli, Angela Ortenzi, Alfredo Colantoni, Antonio Di Grazia, Eleonora Franze, Marco Colella, Davide Di Fusco, Giuseppe S. Sica, Ivan Monteleone, Giovanni Monteleone, Carmine Stolfi
Summary: Colorectal cancer is a major cause of cancer-related death, and current treatments are not effective against advanced disease. Researchers have found that the anthelmintic drug rafoxanide can enhance the sensitivity of colorectal cancer cells to TRAIL, a targeted therapy. This discovery suggests that rafoxanide could be a potential treatment option for overcoming TRAIL resistance in colorectal cancer.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Biochemistry & Molecular Biology
Anne Yagolovich, Artem A. Artykov, Alina A. Isakova, Yekaterina V. Vorontsova, Dmitry A. Dolgikh, Mikhail P. Kirpichnikov, Marine E. Gasparian
Summary: In the past two decades, bifunctional proteins have been created to enhance therapeutic effects in various diseases. This study focuses on the design and optimization of a fusion protein, HRH-DR5-B, to enhance the efficacy of the anti-cancer cytokine TRAIL. The optimized SRH-DR5-B fusion protein showed high affinity binding to specific receptors and increased cytotoxic activity in tumor spheroids.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Liang Ma, Hong-Ling Wei, Ke-Jie Wang, Xiang-Yu Meng, Sai-Qi Ni, Cheng Zhou, Yi Li, Rui Yu, Qi Ma
Summary: This study found that the combination of rhein (RH) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can inhibit the proliferation and induce apoptosis of bladder cancer cells, suggesting its potential value in clinical treatment.
Article
Biochemistry & Molecular Biology
Suchanoot Kutpruek, Kanchana Suksri, Petcharee Maneethorn, Namoiy Semprasert, Pa-thai Yenchitsomanus, Suwattanee Kooptiwut
Summary: Our study demonstrates that dexamethasone induces pancreatic beta-cell apoptosis by upregulating TRAIL and DR5 expression, while imatinib can protect against it by reducing their expression. This finding is significant in preventing steroid-induced diabetes.
JOURNAL OF CELLULAR BIOCHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Taiga Seki, Yui Shimizu, Kyota Ishii, Yuzuki Takahama, Kazunori Kato, Tomohiro Yano
Summary: The study showed that NK cells can selectively target androgen-dependent prostate cancer stem-like cells via the TRAIL/DR5 pathway, providing a basis for developing strategies to eliminate prostate cancer stem cells.
Article
Pharmacology & Pharmacy
Danyang Zhao, Lei Yang, Peng Han, Haihui Zhang, Fanjun Wang, Zhiyun Meng, Hui Gan, Zhuona Wu, Wenzhong Sun, Chuan Chen, Guifang Dou, Ruolan Gu
Summary: This study found that soluble death receptor 5 fusion protein (sDR5-Fc) effectively inhibited excessive apoptosis in radiation-sensitive tissues and mitigated radiation-induced damage. It also improved abnormal biochemical indicators, regulated immune cell numbers, and reduced blood cell death. In vitro experiments showed that sDR5-Fc effectively inhibited apoptosis of human intestinal mucosal epithelial cells and IEC-6 cells. Survival studies demonstrated that sDR5-Fc administration significantly increased the 30-day survival of mice after whole body radiation. These findings suggest that the DR5-mediated apoptosis pathway plays a crucial role in ARS injury and that DR5 may be a potential therapeutic target. sDR5-Fc, as a DR5 apoptosis antagonist, may be a promising anti-ARS drug candidate deserving further investigation.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Environmental Sciences
Haojie Li, Junjiang Fan, Yangfei Zhao, Jiarong Yang, Huimiao Xu, Ram Kumar Manthari, Xiaofang Cheng, Jundong Wang, Jinming Wang
Summary: The study shows that long-term excessive intake of fluoride can cause kidney damage and apoptosis, while dietary calcium supplementation can alleviate this damage. Calcium supplementation mitigates fluoride-induced kidney apoptosis through various signaling pathways.
ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY
(2021)
Article
Medicine, General & Internal
Joaquin Marco-Brualla, Diego de Miguel, Luis Martinez-Lostao, Alberto Anel
Summary: The resistance of cancer cells to treatments is a significant challenge. However, a new TRAIL formulation called LUV-TRAIL has shown promising results by increasing apoptosis in numerous tumor cell types. Additionally, the metabolic drug DCA has the potential to enhance the sensitivity of cancer cells resistant to LUV-TRAIL, making it a suitable option to overcome TRAIL resistance.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Tak Gyeom Lee, Seon Min Woo, Seung Un Seo, Shin Kim, Jong-Wook Park, Young-Chae Chang, Taeg Kyu Kwon
Summary: This study found that inhibition of the deubiquitinase USP2 enhances TRAIL-induced apoptosis in cancer cells, but not in normal cells. Mechanistically, USP2 interacts with survivin and promotes its ubiquitination and degradation. The findings suggest that targeting USP2 could be a potential strategy for enhancing apoptosis in cancer therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, Research & Experimental
Yusuf A. Haggag, Mohamed A. Osman, Sanaa A. El-Gizawy, Ahmed E. Goda, Maha M. Shamloula, Ahmed M. Faheem, Paul A. McCarron
BIOMEDICINE & PHARMACOTHERAPY
(2018)
Article
Pharmacology & Pharmacy
Ahmed E. Goda, Makoto Koyama, Yoshihiro Sowa, Khaled M. Elokely, Tatsushi Yoshida, Bo-Yeon Kim, Toshiyuki Sakai
BIOCHEMICAL PHARMACOLOGY
(2013)
Article
Oncology
Makoto Koyama, Yasuyuki Izutani, Ahmed E. Goda, Taka-aki Matsui, Mano Horinaka, Mitsuhiro Tomosugi, Jun Fujiwara, Yoshitaka Nakamura, Miki Wakada, Shingo Yogosawa, Yoshihiro Sowa, Toshiyuki Sakai
CLINICAL CANCER RESEARCH
(2010)
Article
Oncology
Kimihiro Yano, Mano Horinaka, Tatsushi Yoshida, Takashi Yasuda, Hiroya Taniguchi, Ahmed E. Goda, Miki Wakada, Sae Yoshikawa, Terukazu Nakamura, Akihiro Kawauchi, Tsuneharu Miki, Toshiyuki Sakai
INTERNATIONAL JOURNAL OF ONCOLOGY
(2011)
Article
Oncology
Hiroya Taniguchi, Mano Horinaka, Tatsushi Yoshida, Kimihiro Yano, Ahmed E. Goda, Shusuke Yasuda, Miki Wakada, Toshiyuki Sakai
MOLECULAR CANCER THERAPEUTICS
(2012)
Article
Oncology
Ahmed E. Goda, Raymond L. Erikson, Toshiyuki Sakai, Jong-Seog Ahn, Bo-Yeon Kim
MOLECULAR ONCOLOGY
(2015)
Article
Oncology
Makoto Koyama, Yoshihiro Sowa, Mano Horinaka, Ahmed E. Goda, Jun Fujiwara, Toshiyuki Sakai
Article
Pharmacology & Pharmacy
Ahmed E. Goda, Alaa E. Elsisi, Samia S. Sokkar, Noha M. Abdelrazik
TOXICOLOGY AND APPLIED PHARMACOLOGY
(2020)
Article
Medicine, Research & Experimental
Nahla E. El-Ashmawy, Abdel-Halim A. Lashin, Kamal M. Okasha, Amal M. Abo Kamer, Tarek M. Mostafa, Mona El-Aasr, Ahmed E. Goda, Yusuf A. Haggag, Haytham O. Tawfik, Mariam A. Abo-Saif
Summary: Studies suggest that tramadol may be a promising drug for treating COVID-19 patients due to its anti-inflammatory, immune-enhancing, and anticoagulant effects.
MEDICAL HYPOTHESES
(2021)
Article
Pharmacology & Pharmacy
Noha D. Fayed, Ahmed E. Goda, Ebtesam A. Essa, Gamal M. El Maghraby
Summary: Atorvastatin, the most commonly used hypolipidemic drug, has problematic biopharmaceutical characteristics that require high doses with potential unwanted side effects. This study investigates chitosan-encapsulated niosomes for enhanced oral delivery of atorvastatin and finds that they have better antihyperlipidemic effects, making them a promising carrier for oral administration of atorvastatin.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2021)
Article
Medicine, Research & Experimental
Ahmed E. Goda, Amr M. Elenany, Alaa E. Elsisi
Summary: Trifluoperazine demonstrates protective effects against doxorubicin-induced cardiotoxicity by alleviating heart failure, inflammation, and myofibril degeneration. Furthermore, trifluoperazine improves renal and hepatic impairments caused by doxorubicin, suggesting its potential in ameliorating organ toxicity.
Article
Pharmacology & Pharmacy
Suleiman S. El Tokhy, Sanaa A. Elgizawy, Mohammed A. Osman, Ahmed E. Goda, Larry D. Unsworth
Summary: This study optimized the encapsulation of dexamethasone disodium phosphate (Dex) in protein-based nanoparticles (NPs) and investigated its effect on the secondary structure of the protein. The optimized NPs exhibited excellent anti-inflammatory activity in vivo.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2022)
Article
Pharmacology & Pharmacy
A. E. GODA, T. SAKAI
Summary: In this study, the researchers investigated the effects of SB225002 in SW480 human colorectal adenocarcinoma cells and found that it has antimitotic activity and induces cell death. Mechanistically, SB225002 activates the CHK1 checkpoint and JNK signaling, and mediates cytotoxicity by increasing intracellular ROS.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2022)
Article
Pharmacology & Pharmacy
M. F. Saleh, M. E. Elsayad, A. E. Goda
Summary: The study demonstrates the potential of DCA in protecting against acute DOX cardiotoxicity at therapeutically feasible dose by restoring mitochondrial function to promote cardiac protection.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2021)
Article
Oncology
Ahmed E. Goda, Raymond L. Erikson, Jong-Seog Ahn, Bo-Yeon Kim
ANTICANCER RESEARCH
(2015)